143 related articles for article (PubMed ID: 36879012)
1. A multicenter phase II trial of anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative breast cancer.
Mamot C; Wicki A; Hasler-Strub U; Riniker S; Li Q; Holer L; Bärtschi D; Zaman K; von Moos R; Dedes KJ; Boos LA; Novak U; Bodmer A; Ritschard R; Obermann EC; Tzankov A; Ackermann C; Membrez-Antonioli V; Zürrer-Härdi U; Caspar CB; Deuster S; Senn M; Winterhalder R; Rochlitz C
Sci Rep; 2023 Mar; 13(1):3705. PubMed ID: 36879012
[TBL] [Abstract][Full Text] [Related]
2. Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study.
Mamot C; Ritschard R; Wicki A; Stehle G; Dieterle T; Bubendorf L; Hilker C; Deuster S; Herrmann R; Rochlitz C
Lancet Oncol; 2012 Dec; 13(12):1234-41. PubMed ID: 23153506
[TBL] [Abstract][Full Text] [Related]
3. Tumor targeting using anti-her2 immunoliposomes.
Park JW; Kirpotin DB; Hong K; Shalaby R; Shao Y; Nielsen UB; Marks JD; Papahadjopoulos D; Benz CC
J Control Release; 2001 Jul; 74(1-3):95-113. PubMed ID: 11489487
[TBL] [Abstract][Full Text] [Related]
4. Targeting immunoliposomes to EGFR-positive glioblastoma.
Kasenda B; König D; Manni M; Ritschard R; Duthaler U; Bartoszek E; Bärenwaldt A; Deuster S; Hutter G; Cordier D; Mariani L; Hench J; Frank S; Krähenbühl S; Zippelius A; Rochlitz C; Mamot C; Wicki A; Läubli H
ESMO Open; 2022 Feb; 7(1):100365. PubMed ID: 34998092
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial.
Liu J; Liu Q; Li Y; Li Q; Su F; Yao H; Su S; Wang Q; Jin L; Wang Y; Lau WY; Jiang Z; Song E
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32448804
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.
Curigliano G; Pivot X; Cortés J; Elias A; Cesari R; Khosravan R; Collier M; Huang X; Cataruozolo PE; Kern KA; Goldhirsch A
Breast; 2013 Oct; 22(5):650-6. PubMed ID: 23958375
[TBL] [Abstract][Full Text] [Related]
7. Macrophage-Derived Extracellular Vesicles as Drug Delivery Systems for Triple Negative Breast Cancer (TNBC) Therapy.
Haney MJ; Zhao Y; Jin YS; Li SM; Bago JR; Klyachko NL; Kabanov AV; Batrakova EV
J Neuroimmune Pharmacol; 2020 Sep; 15(3):487-500. PubMed ID: 31722094
[TBL] [Abstract][Full Text] [Related]
8. Anti-CD44 and EGFR Dual-Targeted Solid Lipid Nanoparticles for Delivery of Doxorubicin to Triple-Negative Breast Cancer Cell Line: Preparation, Statistical Optimization, and
Darabi F; Saidijam M; Nouri F; Mahjub R; Soleimani M
Biomed Res Int; 2022; 2022():6253978. PubMed ID: 35845934
[TBL] [Abstract][Full Text] [Related]
9. Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial).
Rinnerthaler G; Gampenrieder SP; Petzer A; Burgstaller S; Fuchs D; Rossmann D; Balic M; Egle D; Rumpold H; Singer CF; Bartsch R; Petru E; Melchardt T; Ulmer H; Mlineritsch B; Greil R
BMC Cancer; 2018 Nov; 18(1):1074. PubMed ID: 30400780
[TBL] [Abstract][Full Text] [Related]
10. Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer.
Brinkman AM; Chen G; Wang Y; Hedman CJ; Sherer NM; Havighurst TC; Gong S; Xu W
Biomaterials; 2016 Sep; 101():20-31. PubMed ID: 27267625
[TBL] [Abstract][Full Text] [Related]
11. Doxorubicin-Loaded Micelle Targeting MUC1: A Potential Therapeutic for MUC1 Triple Negative Breast Cancer Treatment.
Khondee S; Chittasupho C; Tima S; Anuchapreeda S
Curr Drug Deliv; 2018; 15(3):406-416. PubMed ID: 28707580
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.
Mamot C; Drummond DC; Greiser U; Hong K; Kirpotin DB; Marks JD; Park JW
Cancer Res; 2003 Jun; 63(12):3154-61. PubMed ID: 12810643
[TBL] [Abstract][Full Text] [Related]
13. Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells.
Mamot C; Ritschard R; Wicki A; Küng W; Schuller J; Herrmann R; Rochlitz C
J Drug Target; 2012 Jun; 20(5):422-32. PubMed ID: 22519893
[TBL] [Abstract][Full Text] [Related]
14. EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells.
Mamot C; Ritschard R; Küng W; Park JW; Herrmann R; Rochlitz CF
J Drug Target; 2006 May; 14(4):215-23. PubMed ID: 16777680
[TBL] [Abstract][Full Text] [Related]
15. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.
Yardley DA; Brufsky A; Coleman RE; Conte PF; Cortes J; Glück S; Nabholtz JM; O'Shaughnessy J; Beck RM; Ko A; Renschler MF; Barton D; Harbeck N
Trials; 2015 Dec; 16():575. PubMed ID: 26673577
[TBL] [Abstract][Full Text] [Related]
16. Panitumumab, Gemcitabine, and Carboplatin as Treatment for Women With Metastatic Triple-Negative Breast Cancer: A Sarah Cannon Research Institute Phase II Trial.
Yardley DA; Ward PJ; Daniel BR; Eakle JF; Lamar RE; Lane CM; Hainsworth JD
Clin Breast Cancer; 2016 Oct; 16(5):349-355. PubMed ID: 27340049
[TBL] [Abstract][Full Text] [Related]
17. Combined mTOR inhibitor rapamycin and doxorubicin-loaded cyclic octapeptide modified liposomes for targeting integrin α3 in triple-negative breast cancer.
Dai W; Yang F; Ma L; Fan Y; He B; He Q; Wang X; Zhang H; Zhang Q
Biomaterials; 2014 Jul; 35(20):5347-5358. PubMed ID: 24726747
[TBL] [Abstract][Full Text] [Related]
18. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
Wu YL; Cheng Y; Zhou J; Lu S; Zhang Y; Zhao J; Kim DW; Soo RA; Kim SW; Pan H; Chen YM; Chian CF; Liu X; Tan DSW; Bruns R; Straub J; Johne A; Scheele J; Park K; Yang JC;
Lancet Respir Med; 2020 Nov; 8(11):1132-1143. PubMed ID: 32479794
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Limertinib (ASK120067) in Patients With Locally Advanced or Metastatic EGFR Thr790Met-Mutated NSCLC: A Multicenter, Single-Arm, Phase 2b Study.
Shi Y; Li B; Wu L; Pan Y; Pan Z; Liu Y; Fan Y; Ji Y; Fang J; Shi Q; Shi J; Gao H; Hu Y; Wang X; He Z; Ma R; Zhang Y; Jiang D; Bai Y; Zhang Y; Huang L; Zhou T; Liu H; Wang D; Wen Q; Chen G; Zang A; Wang X; Zhang X; Hu J; Yang R; Zhang G; Gu K; Wang L; Wang Q; Wei Z; Li Z; Lu H; Zhang H; Chen H; Song T
J Thorac Oncol; 2022 Oct; 17(10):1205-1215. PubMed ID: 35659581
[TBL] [Abstract][Full Text] [Related]
20. Anti-HER2 immunoliposomes for targeted therapy of human tumors.
Park JW; Hong K; Kirpotin DB; Meyer O; Papahadjopoulos D; Benz CC
Cancer Lett; 1997 Oct; 118(2):153-60. PubMed ID: 9459205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]